NCT06846671 2026-04-16
CaDAnCe-302
BeOne Medicines
Phase 3 Recruiting
Clinical Trials
13 trialsNCT06191744 2026-04-13
EPCOREâ„¢FL-2
Genmab
Phase 3 Recruiting
NCT05139017 2026-04-07
waveLINE-003
Merck Sharp & Dohme LLC
Phase 2/3 Recruiting
NCT06522737 2026-04-06
TERZO
SecuraBio
Phase 3 Recruiting
NCT06084936 2026-04-02
GLOBRYTE
Hoffmann-La Roche
Phase 3 Recruiting
NCT07139873 2026-03-27
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
Dizal Pharmaceuticals
Phase 3 Recruiting
NCT06091254 2026-03-11
OLYMPIA-1
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT06970743 2026-01-07
CaDAnCe-303
BeOne Medicines
Phase 3 Recruiting
NCT07189065 2025-12-16
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 2 Recruiting
NCT06241456 2025-12-09
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Recruiting
NCT06911502 2025-12-05
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Celgene
Phase 3 Recruiting
NCT04792489 2025-04-24
DALY II USA/ MB-CART2019.1 for DLBCL
Miltenyi Biomedicine GmbH
Phase 2 Recruiting
NCT06363994 2024-12-27
A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
InnoCare Pharma Inc.
Phase 3 Recruiting